(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.
The stock was 15% higher in early trade in London at 48.49 pence a share.
Ensifentrine was created for the maintenance treatment of chronic obstructive pulmonary disease.
The clinical stage biopharmaceutical company said all of the primary and secondary lung function endpoints were met in the second-phase trial.
"The magnitude of improvement in lung function and duration of action were highly statistically significant and support twice daily dosing of ensifentrine for the treatment of chronic obstructive pulmonary disease," the company said in its statement Monday.
